Oarsman Capital Inc. Has $1.20 Million Holdings in Pfizer Inc. (PFE)

Oarsman Capital Inc. reduced its stake in Pfizer Inc. (NYSE:PFE) by 4.1% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 32,929 shares of the biopharmaceutical company’s stock after selling 1,425 shares during the period. Oarsman Capital Inc.’s holdings in Pfizer were worth $1,195,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PFE. Charles Schwab Investment Advisory Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at $286,229,000. Dimensional Fund Advisors LP lifted its stake in shares of Pfizer by 15.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock valued at $1,967,651,000 after purchasing an additional 7,059,171 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after purchasing an additional 6,785,335 shares during the last quarter. Jensen Investment Management Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at $110,291,000. Finally, Fisher Asset Management LLC lifted its stake in shares of Pfizer by 4.4% in the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock valued at $1,431,069,000 after purchasing an additional 1,671,311 shares during the last quarter. Institutional investors own 68.64% of the company’s stock.

In other news, major shareholder Pfizer Inc bought 55,556 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the purchase, the insider now owns 21,976,484 shares in the company, valued at $395,576,712. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

PFE opened at $43.51 on Monday. Pfizer Inc. has a 12-month low of $33.20 and a 12-month high of $45.81. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47. The stock has a market cap of $259.01 billion, a P/E ratio of 16.42, a PEG ratio of 2.19 and a beta of 0.88.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The firm had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. During the same quarter in the prior year, the company earned $0.67 EPS. Pfizer’s revenue was up 1.0% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 3 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.13%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s payout ratio is 51.32%.

Several brokerages have recently commented on PFE. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the company a “buy” rating in a research note on Monday, August 27th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, July 31st. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $42.00 price target on shares of Pfizer in a research note on Wednesday, August 1st. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Monday, August 6th. Finally, Deutsche Bank set a $45.00 price target on Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $42.67.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.chaffeybreeze.com/2018/11/19/oarsman-capital-inc-has-1-20-million-holdings-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: Yield Curve

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply